My watch list
my.bionity.com  
Login  

p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes

Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor-4 (CXCR4) and chemokine receptor-7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5+ endosomes as serine-phosphoproteins bound to β-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and β-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.

Authors:   Laura Patrussi; Nagaja Capitani; Francesca Cattaneo; Noemi Manganaro; Alessandra Gamberucci; Federica Frezzato; Veronica Martini; Andrea Visentin; Pier Giuseppe Pelicci; Mario M. D’Elios; Livio Trentin; Gianpietro Semenzato; Cosima T. Baldari
Journal:   Oncogene
Year:   2018
Pages:   1
DOI:   10.1038/s41388-017-0066-2
Publication date:   12-Jan-2018
Facts, background information, dossiers
  • organs
  • ibrutinib
More about Nature Publishing Group
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE